ReShape Lifesciences Inc.
RSLS
$0.63
-$0.0055-0.87%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 72.98% | 74.09% | 73.21% | 75.36% | 60.61% |
| Total Depreciation and Amortization | -96.37% | -94.03% | -93.22% | -92.85% | -69.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -101.03% | -96.76% | -97.44% | -107.43% | -74.78% |
| Change in Net Operating Assets | 140.56% | 91.74% | -384.27% | -683.07% | -7,687.10% |
| Cash from Operations | 64.25% | 56.29% | 28.66% | 22.56% | 22.97% |
| Capital Expenditure | 100.00% | 100.00% | 72.52% | 67.18% | -2.52% |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | 10.00% | -15.38% | -15.38% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 100.00% | 97.03% | 89.13% | 97.11% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -60.68% | -60.69% | -44.69% | 461.47% | 425.24% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | -- | -- | -- | -- |
| Cash from Financing | -56.98% | -60.69% | -44.69% | 461.47% | 411.68% |
| Foreign Exchange rate Adjustments | 123.08% | 122.73% | 86.36% | -100.00% | -166.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 84.97% | 48.90% | -3.56% | 103.20% | 79.63% |
